CXCR3 and melanoma: In the setting of combination DC–Pool Peptide vaccines, improved treatment benefits in our B16 melanoma model were associated with a pro-inflammatory TME characterized by increased CD8+ TIL and CD11c+ DC content, increased TME expression of CXCL10 (a recruiting chemokine for activated CXCR3+ T cells [35]), and reduced CD31+ VEC, CD4+Foxp3+ Treg, and CD11b+Gr1+ MDSC content.